A possible method is to analyze the plasma for driver mutations identified in the tumor, e.g., epidermal growth factor receptor (EGFR) exon 21 p.L858R or Kirsten rat sarcoma (KRAS) exon 2 p.G12D. This evidence concerns the gene KRAS and neoplasm.